

RIC-Mel Network - Network for Research and Clinical Investigation on Melanoma - French national cohort of melanoma patients

Head :Pr Dréno Brigitte, CRCINA - Unité Inserm U1232 - Responsable Equipe 2 "Clinical and translational research in skin cancer"
Pr Lebbe Céleste

Last update : 02/04/2021 | Version : 5 | ID : 5135

General

Identification

Detailed name Network for Research and Clinical Investigation on Melanoma - French national cohort of melanoma patients

Sign or acronym RIC-Mel Network

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL: EGY/EM/AR124131

General Aspects

Medical area Cancer research
Dermatology, venereology

Pathology (details) Melanoma

Keywords Melanoma, network, cohort, epidemiology, preclinical to phase III studies, national, european and international instances, fondamentale and translational research.

Scientific investigator(s) (Contact)

Name of the director Pr Dréno

Surname Brigitte

Address CHU de Nantes
Service de Dermatologie
Site Hôtel Dieu
1, place Alexis Ricordeau
44093 Nantes cedex 01

Phone -

Email	brigitte.dreno@atlanmed.fr
Unit	CRCINA - Unité Inserm U1232 - Responsable Equipe 2 "Clinical and translational research in skin cancer"
Organization	Centre de Recherche en Cancérologie et Immunologie Nantes Angers

Name of the director	Pr Lebbe
Surname	Céleste
Address	Assistance Publique des Hôpitaux de Paris Hôpital Saint Louis Service de Dermatologie 1, avenue Claude Vellefaux 75010 Paris
Phone	-
Email	celeste.lebbe@sls.aphp.fr
Organization	Hôpital Saint-Louis (AP-HP)

Collaborations

Participation in projects, networks and consortia	Yes
---------------------------------------------------	-----

Details	Our partners : the Cancerology Group (GCC) of the French Society of Dermatology (SFD), the clinico-biologico-radiological database MELBASE, the Ile de France Melanoma network, the Far West Biotherapies and Researches in Dermatology network (BIORDERM), the West Melanoma Network and the patients association AMESA.
---------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Funding

Funding status	Mixed
----------------	-------

Details	-
---------	---

Governance of the database

Sponsor(s) or organisation(s) responsible	CHU de Nantes - RIC-Mel coordinating center
-------------------------------------------	---------------------------------------------

Organisation status	Public
---------------------	--------

Sponsor(s) or organisation(s) responsible	Cancerology Group (GCC) of the French Society of Dermatology (SFD)
-------------------------------------------	--------------------------------------------------------------------

Organisation status	Public
---------------------	--------

Presence of scientific or steering committees Yes

Additional contact

Name of the contact	Varey (Chef de projet)
Surname	Emilie
Address	CHU de Nantes - Hôtel Dieu 1, place Alexis Ricordeau 44093 NANTES Cedex 01
Phone	02 40 08 78 85
Email	emilie.varey@chu-nantes.fr
Organization	CHU de Nantes

Main features

Type of database

Type of database Study databases

Study databases (details) Cohort study

Database recruitment is carried out by an intermediary A selection of health institutions and services

Database recruitment is carried out as part of an interventional study No

Additional information regarding sample selection. After 7 years in existence, 23,971 patients have been included in database by our 49 participating centers.

Database objective

Main objective

- To federate the clinical cancerology and dermatology sites as well as the existing networks in melanoma around a common database,
- To be a preferred interlocutor for the industry,
- To ensure close interaction between all the hospital disciplines involved in melanoma evolution,
- To ensure the functioning of a clinical database,
- To ensure interactions between clinical and translational research as well as to support basic research.

Inclusion criteria	Patients with melanoma, regardless of the location of the primary tumour (cutaneous, mucosal, ocular or unknown) and the stage, and who have accepted to participate.
Population type	
Age	Adolescence (13 to 18 years) Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Pathology	C00-C97 - Malignant neoplasms
Gender	Male Woman
Geography area	National
Detail of the geography area	France
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	March 2012
Size of the database	
Size of the database (number of individuals)	Greater than 20 000 individuals
Details of the number of individuals	23,971 patients (1 April, 2019)
Data	
Database activity	Current data collection
Type of data collected	Clinical data
Clinical data (detail)	Direct physical measures Medical registration
Details of collected clinical data	Data relating to the primitiv tumour, disease evolution (stage, treatments...) until death.

Presence of a biobank	No
Health parameters studied	Health event/morbidity Health event/mortality

Procedures

Data collection method	Data are collected during patient follow-up, after expressing its consent
Participant monitoring	Yes
Details on monitoring of participants	Patients come as part of their usual medical care. The updating of data only occurs in case of disease progression and until the death.
Links to administrative sources	No

Promotion and access

Promotion

Link to the document	Plaquette_informative_du_reseau_RIC-Mel, RIC-Mel-DI-002, v.07.pdf
Link to the document	Book_academique_RIC-Mel_CID_2016.pdf
Description	Academic book on the RIC-Mel network created for the Cohort Innovation Day 2016, organised by AVIESAN and ARIIS with the support of INSERM Transfert
Link to the document	Poster_IID_DRAFT_5.pdf
Description	Poster presented at the International Investigative Dermatology congress in 2018
Other information	First publication : Dalle S. et al., Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database. Eur J Dermatol . 2020, 30(4):389-396

Access

Presence of document that lists variables and coding procedures	Yes
Terms of data access (charter for data provision, format of data, availability delay)	Please contact : Mr Amir KHAMMARI Deputy coordinator of the RIC-Mel network Tel. : +33 2.40.08.32.80

Mail : amir.khammari@chu-nantes.fr

Mrs Emilie VAREY

Project manager of the RIC-Mel network

Tel. : +33 2.40.08.78.85

Mail : emilie.varey@chu-nantes.fr

Access to aggregated data

Access on specific project only

Access to individual data

No access